Finally, consistent with our pre-clinical data in vitro, the analyses from two distinct clinical datasets, TGCA and Rembrandt databases, demonstrate that GBM patients with high levels of the five genes signature, including α6-integrin and its targets, CHK1, ZEB1, OLIG2 and SOX2, have a significantly shorter overall survival as compared with patients with lower expression. This evidence concerns the gene OLIG2 and glioblastoma.